妇科恶性肿瘤脑转移瘤的肿瘤免疫微环境。
Tumor immune microenvironment in brain metastases from gynecologic malignancies.
机构信息
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
出版信息
Cancer Immunol Immunother. 2021 Oct;70(10):2951-2960. doi: 10.1007/s00262-021-02909-4. Epub 2021 Mar 13.
INTRODUCTION
The density and distribution of the tumor immune microenvironment associated with brain metastases (BM) from gynecologic malignancies are unknown and have not been previously reported. We sought to describe the clinical features of a cohort of patients with BM from gynecologic malignancies and to characterize the tumor immune microenvironment from available archival surgical specimens.
METHODS
We performed a retrospective review of electronic medical records from 2002 to 2018 for patients with BM from gynecologic malignancies. Data on patient characteristics, treatment regimens, and clinical outcomes were procured. CD4, CD8, CD45RO, CD68, CD163, and FOXP3 immunohistochemistry were evaluated from available archival surgical specimens from primary disease site and neurosurgical resection.
RESULTS
A cohort of 44 patients with BM from gynecologic malignancies was identified, 21 (47.7%) endometrial primaries and 23 (52.3%) ovarian primaries. Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) were evaluated in 13 primary cases and 15 BM cases. For the 13 primary cases, CD4 TILs were evident in 76.9% of cases, CD8 in 92.3%, CD45RO in 92.3%, and FOXP3 in 46.2%, as well as CD68 TAMs in 100% and CD163 in 100%. For the 15 BM cases, CD4 TILs were evident in 60.0% of cases, CD8 in 93.3%, CD45RO in 73.3%, and FOXP3 in 35.7%, as well as CD68 TAMs in 86.7% and CD163 in 100%.
CONCLUSION
An active tumor immune microenvironment is present with similar distribution in the primary disease site and BM from patients with gynecologic malignancies.
简介
与妇科恶性肿瘤脑转移（BM）相关的肿瘤免疫微环境的密度和分布尚不清楚，也尚未有报道。我们旨在描述一组妇科恶性肿瘤脑转移患者的临床特征，并从现有存档的手术标本中描述肿瘤免疫微环境。
方法
我们对 2002 年至 2018 年期间患有妇科恶性肿瘤脑转移的患者的电子病历进行了回顾性分析。获取了患者特征、治疗方案和临床结局的数据。对原发疾病部位和神经外科切除的可用存档手术标本进行了 CD4、CD8、CD45RO、CD68、CD163 和 FOXP3 的免疫组化评估。
结果
确定了一组 44 例妇科恶性肿瘤脑转移患者，其中 21 例（47.7%）为子宫内膜原发癌，23 例（52.3%）为卵巢原发癌。在 13 例原发癌和 15 例 BM 病例中评估了肿瘤浸润淋巴细胞（TILs）和肿瘤相关巨噬细胞（TAMs）。对于 13 例原发癌，76.9%的病例存在 CD4 TILs，92.3%的病例存在 CD8 TILs，92.3%的病例存在 CD45RO TILs，46.2%的病例存在 FOXP3 TILs，100%的病例存在 CD68 TAMs 和 100%的病例存在 CD163 TAMs。对于 15 例 BM 病例，60.0%的病例存在 CD4 TILs，93.3%的病例存在 CD8 TILs，73.3%的病例存在 CD45RO TILs，35.7%的病例存在 FOXP3 TILs，86.7%的病例存在 CD68 TAMs 和 100%的病例存在 CD163 TAMs。
结论
患有妇科恶性肿瘤的患者，原发疾病部位和 BM 中存在活跃的肿瘤免疫微环境，且分布相似。
Zotero 插件